Related by context. All words. (Click for frequent words.) 67 Study AREDS 63 Eye Disease 62 VADT 62 Diabetic Retinopathy 61 Clinical Antipsychotic Trials 60 STRIDE PD 60 bile acid metabolism 60 PROactive study 60 Framingham Offspring Study 60 selenium supplementation 60 Intervention Effectiveness CATIE 60 ruboxistaurin 60 Intervention Effectiveness 59 AIM HIGH 59 fenretinide 59 Complications Trial 59 Ocular Hypertension Treatment 59 BARI 2D 59 Zeaxanthin 59 riociguat 58 prospective randomized placebo 58 PLCO 58 neovascular AMD 58 ONTARGET 58 placebo controlled clinical 58 ExTRACT TIMI 58 RE LY trial 58 Intervention Trial GAIT 58 prospective multicentre 58 STEP BD 58 Aggressive Reduction 58 ACCORD Eye 57 phase IIIb 57 Diabetic Macular Edema 57 Neovascular AMD 57 ADVANCE PD 57 prospective nonrandomized 57 choroidal neovascularization 57 LUMINATE 57 Prostate Cancer Prevention 57 diabetic retinopathy 57 SWOG 57 double blinded placebo 57 BRIM3 57 double blinded randomized 57 CRVO 57 Prostate Lung Colorectal 57 Stop Hypertension diet 57 atherogenic dyslipidemia 57 retrospective cohort 57 Cholesterol Levels SPARCL 57 multicenter randomized controlled 57 prospective observational cohort 57 Trandolapril 56 Screening Trial DMIST 56 testosterone supplementation 56 dietary supplementation 56 Women Ischemia Syndrome 56 Prospective Randomized 56 GAMMAGARD 56 lutein 56 Squalamine 56 Lucentis ranibizumab 56 Dialysis Outcomes 56 ALLHAT 56 T1DM 56 p# biomarker 56 Health Initiative Observational 56 Digital Mammographic Imaging 56 MERLIN TIMI 56 chromium supplementation 56 NHANES III 56 Carotid Revascularization Endarterectomy vs. 56 RE LY 56 Hepatocellular Carcinoma HCC 56 Phase IIB 56 dietary carbohydrate 56 neovascular 56 HPTN 56 substudy 56 Singh Manoux 56 eprotirome 56 antihypertensive therapy 56 Screening Trial 56 journal Ophthalmology 56 ENDEAVOR clinical 56 phase IIa 56 SWiTCH 56 PLCO trial 56 silymarin 56 intravitreal triamcinolone 56 LUX Lung 56 proliferative diabetic retinopathy 55 multicenter phase 55 HF ACTION 55 randomized controlled trials RCTs 55 antioxidant supplementation 55 CAMMS# 55 serum vitamin D 55 NICE SUGAR 55 Stop Hypertension DASH 55 SPARCL 55 subgroup analyzes 55 Haptoglobin 55 diabetic retinopathy DR 55 EVIZON 55 CARE HF 55 Meta analyzes 55 prostate carcinogenesis 55 strontium ranelate 55 macular 55 SCD HeFT 55 Prostate Disease 55 phase Ib 55 NHANES 55 fosbretabulin 55 DCCT 55 paricalcitol 55 prospective multicenter study 55 urolithiasis 55 tarenflurbil 55 COPAXONE R 55 PRECiSE 55 NSABP B 55 pivotal bioequivalence 55 phase IIb clinical 55 Evaluation WISE 55 Dasatinib 55 Phase 2a trial 55 number NCT# ClinicalTrials.gov 55 SNT MC# 55 placebo controlled Phase 55 IMPROVE HF 55 cholinesterase inhibitors 55 PreserVision 55 Subgroup analysis 55 dbGaP 55 GISSI 55 retinal vein occlusion 55 MADIT II 55 neovascular form 55 CALGB 55 GFT# 55 subanalysis 55 HYVET 55 T2D 55 AIR CF1 55 lipid profiles 55 randomized blinded 55 tocotrienols 55 ASTEROID 54 NSABP 54 EchoCRT 54 dietary questionnaires 54 diabetic macular edema DME 54 serum phosphate 54 MADIT CRT 54 Ranibizumab 54 observational cohort 54 Natural S equol 54 confirmatory clinical 54 RE LY ® 54 Cloretazine 54 Stop Hypertension 54 proliferative retinopathy 54 clinical pharmacology studies 54 MDRD 54 diabetic macular edema 54 beta carotene supplementation 54 glaucomatous 54 ADMIRE HF 54 UKPDS 54 dose escalation Phase 54 prospective randomized multicenter 54 dyslipidaemia 54 Ophena TM 54 INTERHEART study 54 Alzheimer Disease Cooperative 54 Ovarian Cancer Screening 54 AVOREN 54 Lutein 54 HGPIN 54 HORIZONS AMI 54 NeuroImage 54 undergoing cataract surgery 54 Glucosamine chondroitin Arthritis 54 prospective longitudinal 54 Central Retinal Vein 54 zeaxanthin 54 ACCORD Lipid 54 multicenter Phase II 54 sorafenib Nexavar 54 cinacalcet 54 dietary antioxidants 54 ACCOMPLISH 54 DASH diet 54 INCB# [003] 54 Dr. Fehlings 54 multicenter placebo controlled 54 SYNTAX trial 54 longitudinal cohort study 54 coronary calcification 54 Nonalcoholic Fatty Liver Disease 54 randomized multicenter trial 54 PFO migraine 54 anterior uveitis 54 metaanalysis 54 PRTX 54 efficacy endpoint 54 #F FDG PET 54 nonrandomized 54 randomized clinical 54 CARDIA 54 Myelodysplastic Syndrome MDS 54 placebo controlled studies 54 Intervention Trial 54 ACTIVE W 54 dietary glycemic index 54 Phase Ib clinical 54 Phase IIA 54 ASSERT 54 dose escalation phase 54 Glucosamine Chondroitin Arthritis 54 Zevalin consolidation 54 SPIRIT FIRST 54 huperzine 54 Cochrane reviewers 54 Microplasmin 54 HCV SPRINT 54 candesartan cilexetil 54 ACUITY trial 54 DMIST 54 Macular Degeneration 54 Polyp Prevention Trial 54 malignant pleural mesothelioma 54 antioxidants lutein 54 metabolic syndrome MetS 54 EoE 54 Cornea Donor Study 54 microalbuminuria 54 randomized controlled clinical 54 antidiabetic medication 54 NATRECOR ® 54 HOPE TOO 54 Patient Registry 54 Wisconsin Sleep Cohort 54 pharmacogenetic testing 54 placebo controlled clinical trials 54 LHON 54 anti angiogenic therapy 54 Phase Ib study 54 KRAS mutation 54 Rosuvastatin 54 journal Hepatology 54 Adult Stem Cell Therapy 54 vildagliptin 53 renoprotective 53 LCP AtorFen 53 ALA PDT 53 multicenter trials 53 HeFH 53 NCI Cancer 53 neovascular age 53 Multiethnic Study 53 BCIRG 53 haplotype map 53 ECASS 53 HIV HCV coinfected 53 relapsed MM 53 APPRAISE 53 dose titration 53 Degarelix 53 serum lipids 53 RRMS patients 53 multicenter randomized clinical 53 Ovarian PLCO Cancer 53 Medidur FA 53 lutein zeaxanthin 53 β blockers 53 cognitively normal 53 ocular disorders 53 AIR2 Trial 53 TG# [003] 53 deferiprone 53 Metabolic Syndrome 53 EVEREST II 53 VaD 53 APTIVUS 53 iPTH 53 randomized crossover 53 randomized controlled clinical trials 53 Retaane 53 Valsartan 53 hyperoxaluria 53 randomized Phase IIb 53 multicentre randomized 53 WHEL 53 aripiprazole Abilify 53 ergocalciferol 53 Geographic Atrophy 53 Velcade bortezomib 53 CARDIA study 53 Thiazolidinediones 53 Randomized Double blind 53 Denufosol 53 canakinumab 53 UDCA 53 pegaptanib 53 lomitapide 53 HoFH 53 neuroprotective effects 53 AVERROES 53 phytonutrient 53 RSD# oral 53 Left Ventricular Dysfunction 53 thorough QT 53 Buijsse 53 Lipid Lowering Treatment 53 Lp PLA 2 53 randomized multicenter 53 lipid lowering therapy 53 glaucoma cataract 53 T2DM 53 Prodarsan ® 53 carotid IMT 53 Neovascular Age Related Macular 53 Renal Cell Carcinoma RCC 53 abacavir Ziagen 53 Prostate Cancer Outcomes 53 inhibitor RG# 53 CATIE 53 nondemented 53 NEVO RES 53 subfoveal choroidal neovascularization 53 EMPOWER ™ 53 folate supplementation 53 Leber congenital amaurosis LCA 53 chemoprevention trials 53 CHAMPION PCI 53 plasma pharmacokinetics 53 PROactive Study 53 APEX AMI trial 53 dietary modification 53 florbetaben 53 Dr. Pasinetti 53 antihypertensive medications 53 skin sterol 53 TAXUS IV 53 Antihypertensive 53 PREVENT IV 53 Dry Eye 53 journal Optometry 53 Edge STudy 53 ADAGIO study 53 donepezil 53 ranibizumab 53 CALGB # [001] 53 Cardiovascular Risk 53 bevasiranib 53 STICH trial 53 ranibizumab Lucentis 53 modENCODE 53 olmesartan 53 Phase 1b trial 53 choroidal vasculopathy 53 ENDEAVOR IV 53 SABCS 53 phase IIb study 53 antitumor effect 53 carotid artery stenting CAS 53 BENICAR HCT 53 prospective observational studies 53 macroalbuminuria 53 International HapMap Project 53 stone formers 53 pharmacokinetic pharmacodynamic 53 ACRIN 53 ASPIRE HIGHER 53 placebo controlled Phase III 53 drusen 53 ORMD 53 CURRENT OASIS 7 53 calcium supplementation 53 hydroxychloroquine 53 reboxetine 53 OHR/AVR# 53 Canadian Multicentre Osteoporosis 53 ENESTnd 53 phase IIa clinical 53 clinicopathological 53 pharmacologic treatments 53 Alzheimer Disease Neuroimaging Initiative 53 cataract formation 53 teriparatide 53 HAART regimens 52 pyridostigmine 52 Acute Stroke 52 MDRD equation 52 rosuvastatin Crestor 52 Catena ® 52 neuropathologic 52 rFVIIa 52 Enzastaurin 52 ConclusionThis 52 antiangiogenic therapy 52 glaucoma cataracts 52 Diabetes Interventions 52 blinded randomized placebo controlled 52 colesevelam HCl 52 Leber congenital amaurosis 52 Severe Primary IGFD 52 hepatic fibrosis 52 SYNTAX Score 52 dysglycemia 52 Dose escalation 52 Barrett Esophagus 52 pharmacologic intervention 52 macular disease 52 Val HeFT 52 TAXUS VI 52 vitreous hemorrhage 52 eosinophilic asthma 52 gallstone disease 52 adrenal function 52 intact parathyroid hormone 52 glitazones 52 quinacrine 52 lipoic acid 52 Phase 1a clinical 52 ToGA 52 antioxidant nutrients 52 Corus CAD 52 serum lipid levels 52 Diabetes ACCORD 52 ARVO 52 neurocognitive function 52 prospective observational 52 macular degeneration 52 EPA eicosapentaenoic acid 52 Cognitive Impairment 52 Perceiva 52 acetonide FA 52 cerebral microbleeds 52 lipoprotein levels 52 Severe Asthma 52 phase IIb trial 52 Multicenter AIDS 52 KRAS variant 52 HORIZONS AMI trial 52 inflammatory biomarkers 52 Wactawski Wende 52 Mipomersen 52 intensive lipid lowering 52 ARMD 52 atherosclerotic vascular disease 52 clinico pathological 52 atrasentan 52 Acute Ischemic Stroke 52 Ozurdex 52 PRESEPT 52 pharmacokinetic PK 52 prematurity ROP 52 CaPSURE 52 PsA 52 phakic 52 Stenting Trial CREST 52 Silodosin 52 oral bisphosphonate 52 Cystatin C 52 bazedoxifene conjugated estrogens 52 Asthma Intervention 52 pharmacokinetic PK study 52 pramlintide 52 basal cell nevus syndrome 52 Atherosclerosis MESA 52 occlusion CRVO 52 lipid parameters 52 Cinquil 52 FDG PET imaging 52 NAFLD 52 Phase IIIb 52 JANUMET 52 hemoglobin A1c HbA1c 52 postmenopausal hormone therapy 52 OLYMPIA registry 52 adenoma recurrence 52 Nord Trøndelag Health 52 Dietary Approaches 52 Pediatric Diabetes 52 CC genotype 52 DHA supplementation 52 probiotic supplementation 52 amnestic mild cognitive impairment 52 Wilmer Eye Institute 52 Keratitis 52 CATIE AD 52 Xelox 52 montelukast 52 differential gene expression 52 conditional logistic regression 52 NATRECOR R 52 multicenter randomized placebo controlled 52 OPT CHF 52 Periodontal Disease 52 See CLINICAL PHARMACOLOGY 52 squalamine 52 International Verapamil SR 52 bimatoprost 52 WTCCC 52 Phase III randomized 52 ubiquinol 52 bone metabolism 52 TrialNet 52 neratinib 52 DAPT Study 52 Phase Ib II 52 photocoagulation 52 antiobesity 52 Microalbuminuria 52 desvenlafaxine succinate 52 elevated intraocular pressure 52 retinal specialists 52 heterozygous familial hypercholesterolemia 52 Pulmonary Arterial Hypertension 52 cortical stimulation 52 Relieve Depression 52 overt nephropathy 52 randomized controlled Phase 52 Multicenter Automatic Defibrillator Implantation 52 atherothrombotic disease 52 latanoprost 52 multicenter multinational 52 triacylglycerol concentrations 52 ETDRS 52 VA# [002] 52 CYP#C# [001] 52 analgesic efficacy 52 lipid lowering agents 52 Scandinavian Simvastatin Survival 52 placebo controlled randomized 52 vWD 52 idraparinux 52 Randomized Clinical Trial 52 remyelination 52 macular edema 52 APOE genotype 52 estimated GFR 52 APPROVe 52 primary hyperparathyroidism 52 randomized Phase 2b 52 Memory Study WHIMS 52 iSONEP 52 CIMZIA ™ 52 Phase III randomized placebo 52 irbesartan 52 multiple logistic regression 52 Randomised controlled trials 52 Kidney Disease Outcomes 52 multivitamin supplementation 52 pramlintide metreleptin combination 52 prospective randomized controlled 52 Biomarkers Consortium 52 viral kinetics 52 prospectively randomized 52 Sequenced Treatment Alternatives 52 Multicenter Phase 52 AGHD 52 ClinicalTrials.gov 52 NESARC 52 candesartan 51 laser photocoagulation 51 PAOD 51 pharmacodynamic effects 51 atypical hemolytic uremic syndrome 51 intensive statin therapy 51 beta carotene lycopene 51 plasma lipid 51 DASH Diet 51 atypical neuroleptics 51 Eye Diseases 51 Docosahexaenoic Acid DHA 51 synthetic retinoid 51 masked placebo controlled 51 Prof. Gozes 51 AZILECT R 51 WHIMS 51 glargine 51 phytoestrogen 51 magnesium intake 51 Leber Hereditary Optic Neuropathy 51 iPrEx 51 Phenoptin 51 zinc supplementation 51 FOSRENOL ® 51 Randomized Phase 51 Benign Prostatic Hyperplasia 51 macular pigment 51 intravitreal bevacizumab 51 Topiramate 51 C Reactive Protein 51 retinal vein occlusion RVO 51 Visual acuity 51 prospective multicenter 51 Lipid Research 51 K DOQI 51 corneal ectasia 51 Nutrition Examination Surveys NHANES 51 BR.# study 51 IMPACT DCM 51 pathophysiological mechanisms 51 folic acid vitamin B6 51 NCT# ClinicalTrials.gov 51 Hepatotoxicity 51 PRADAXA 51 Betaferon ® 51 Celecoxib APC trial 51 erlotinib Tarceva 51 pharmacodynamic PD 51 fructose intake 51 SIMCOR 51 Liraglutide Effect 51 geographic atrophy 51 NOMID 51 MEND CABG 51 genomewide 51 Diabetes Mellitus 51 Spine Patient Outcomes 51 subclinical hypothyroidism 51 cardio metabolic 51 prognostic variables 51 hsCRP levels 51 Recommended Dietary Allowance 51 aminotransferase 51 neurodevelopmental outcomes 51 BRIM2 51 genetic polymorphisms 51 multicentre prospective 51 Chronic Heart Failure 51 Sjögren syndrome 51 ibandronate 51 colorectal adenoma 51 schizophrenia CIAS 51 GH deficiency 51 glulisine 51 Neovascularization 51 TG MV 51 homocysteine concentrations 51 Phase Ib 51 unblinded 51 oral FTY# 51 randomized clinical trials 51 bosentan 51 nutritional supplementation 51 trials RCTs 51 POAG 51 Bipolar Disorders 51 Rilonacept 51 MTWA testing 51 penicillin allergy 51 glaucoma macular degeneration 51 Stargardt Macular Dystrophy 51 ezetimibe simvastatin 51 Phase IIIb study 51 T1a 51 prospectively defined 51 TOHP 51 Wernicke Korsakoff syndrome 51 Avanafil 51 diagnose Alzheimer disease 51 Hydroxyurea 51 relapsing remitting MS RRMS 51 TRITON TIMI 51 amyloid deposition 51 bezafibrate 51 Primary endpoints 51 prospective multicenter randomized 51 EQUIP OB 51 Insulin Resistance Atherosclerosis 51 retrospective cohort study 51 carotid plaque 51 Controlled Trial 51 Randomized controlled 51 elevated LDL cholesterol 51 AA Amyloidosis 51 algal DHA 51 diagnosing Alzheimer disease 51 Genistein 51 nonalcoholic steatohepatitis 51 Investigator Initiated 51 BYSTOLIC 51 induced macular edema 51 antidiabetic drug 51 sunitinib malate 51 DASH Dietary Approaches 51 Ischemic 51 INS# [001] 51 Metabolic Disease 51 retinopathy 51 Concord grape juice 51 resected pancreatic cancer 51 multicenter randomized 51 Keratoconus 51 Fabry Disease 51 Macugen 51 statins cholesterol lowering 51 racemic baclofen 51 ximelagatran 51 ELCAP 51 Simin Nikbin Meydani 51 Molecular Cancer 51 SE5 OH 51 glycemic diet 51 LASEK 51 PRoFESS 51 Pfizer Ophthalmics 51 infantile colic 51 Phase 2a clinical 51 logistic regression models 51 CHARISMA trial 51 hyperphenylalaninemia HPA due 51 diabetes mellitus DM 51 unoprostone isopropyl 51 randomized multicentre 51 label multicenter randomized 51 alpha blocker 51 PD2i ® 51 central corneal thickness 51 Investigative Dermatology 51 meta regression 51 lipid lowering medications 51 psoriatic arthritis PsA 51 diarrhea predominant irritable 51 Phase IIIb clinical 51 Arch Surg 51 randomized Phase III 51 PROactive 51 Protelos 51 related maculopathy 51 Normative Aging Study 51 AZOR 51 EmbraceAC 51 PARTNER Trial 51 Age Related Macular 51 nonarteritic anterior ischemic optic 51 CLARITY TIMI 51 Cardiac Allograft Rejection 51 Urocortin 2 51 FDA Critical Path 51 Aggressive Drug Evaluation 51 flutamide 51 VFEND 51 metreleptin 51 Phase #/#a 51 MAGE A3 ASCI 51 Inhaled corticosteroids 51 elevated homocysteine 51 Proellex TM 51 Critical Limb Ischemia CLI 51 SYNTAX 51 Interstitial Cystitis 51 phase IIb 51 Antiviral Therapy 51 subclinical atherosclerosis 51 macular edema secondary 51 insulin degludec 51 Pioglitazone 51 postmenopausal osteoporotic women 51 topical NSAIDs 51 evaluating mipomersen 51 MIST II 51 ImmuKnow assay 51 factorial design 51 magnesium supplementation 51 colorectal neoplasia 51 BRCA testing 51 HeFT 51 antihypertensive drugs 51 Etanercept 51 vitamin K1 51 HIV lipodystrophy 51 prospective cohort 51 lipid lowering drugs 51 orlistat Xenical 51 vitamin K2 51 dosage regimens 51 lung adenocarcinoma 51 Bucindolol 51 sevelamer 51 relapsing MS 51 myeloproliferative disorders 51 multivitamin supplements 51 Thrombolysis 51 Phase III randomized controlled 51 Biophysical# 51 neovascular diseases 51 retinitis pigmentosa RP 51 Phase Ia 51 visual acuity 51 glycosylated hemoglobin HbA1c 51 beta blocker therapy 51 Intravitreal 51 glatiramer acetate 51 memantine Namenda 51 adjuvant endocrine therapy 51 Actimmune ® 51 SHPT 51 CaPre ™ 51 PRE SURGE 51 teriflunomide 50 MSI #F 50 ENGAGE AF TIMI 50 soy isoflavone 50 CYPHER Stent 50 Acetonide 50 APTIVUS r 50 National Guideline Clearinghouse 50 related macular degeneration 50 serum retinol 50 Leitzmann 50 CP CPPS 50 Histologic 50 nattokinase 50 urate levels 50 efficacy evaluable 50 carotid artery thickness 50 serum triglycerides 50 Homocysteine 50 TAXUS V 50 landmark ATHENA 50 aldosterone antagonists 50 HuMax EGFr 50 epicatechin 50 hypogonadal men 50 serum lipid 50 multicenter Phase 50 dexpramipexole 50 GOUT 50 Systematic Treatment 50 plasma homocysteine 50 NCEP guidelines 50 randomized multicenter Phase III 50 nonalcoholic steatohepatitis NASH 50 Acute Coronary Syndromes 50 PECARN 50 Alpha lipoic acid 50 urinary N telopeptide 50 prospectively stratified 50 Fasudil 50 ascending dose 50 Inflammatory Bowel Diseases 50 secondary efficacy endpoint 50 abstinent alcoholics 50 Phase Ib Clinical Trial 50 metabolite concentrations 50 gastrin analogue TT 50 keratitis 50 blood Phe levels 50 Young Adults CARDIA 50 SAMe 50 kidney urologic 50 Retinitis Pigmentosa RP 50 serum folate concentrations 50 AAT deficiency 50 Wet AMD 50 fluvastatin 50 tipranavir 50 DCCT EDIC 50 registrational Phase 50 venlafaxine Effexor 50 nutrient supplementation 50 Sociodemographic 50 sipuleucel T 50 serum calcium 50 EBMT criteria 50 BOLDER II 50 MADIT 50 benign prostatic hypertrophy BPH 50 Edward Giovannucci 50 Reynolds Risk Score 50 fatty acid supplementation 50 invasive candidiasis 50 glaucoma diabetic retinopathy 50 placebo controlled trials 50 Acute MI 50 Cancer Prevention ATBC 50 Lipoprotein 50 haemodynamic 50 FOLOTYN ® 50 CYPHER R Sirolimus eluting 50 gestational diabetes mellitus 50 Stop Hypertension DASH diet 50 NTx 50 isoflavone supplement 50 HNRCA 50 Juvenile Idiopathic Arthritis 50 SORT OUT III 50 Klotho gene 50 Ramipril 50 Randomized trials 50 cilostazol 50 SJIA 50 triamcinolone 50 green tea catechins 50 Ginkgo biloba 50 fundus photography 50 sDNA 50 haptoglobin 50 EURIDIS 50 dietary interventions 50 Non Alcoholic Steatohepatitis 50 liver fibrosis 50 Cohort Study MACS 50 Observational studies 50 oral antidiabetes drugs 50 MADIT CRT trial 50 vicriviroc 50 Citicoline 50 humanin 50 hepatorenal syndrome 50 lowering homocysteine levels 50 Mild Cognitive Impairment 50 anticlotting drugs 50 Cand5 50 arterial calcification 50 varespladib 50 chromium picolinate 50 GBA mutations 50 cardioprotective effects 50 NO# [002] 50 Phase IIa trial 50 cataract extraction 50 NCCTG N# 50 MACUGEN 50 label multicenter Phase 50 pharmacokinetic characteristics 50 neurogenic orthostatic hypotension 50 Dietary Modification Trial 50 hormone therapy estrogen 50 prucalopride 50 Diabetic Macular Edema DME 50 monovision 50 RCTs 50 Multiple logistic regression 50 randomized trials 50 PDE# inhibitors 50 narcolepsy cataplexy 50 NAMCS 50 randomized placebo controlled 50 PPMI 50 synbiotic 50 Cochrane Systematic Review 50 L carnitine 50 glycated hemoglobin 50 Kaplan Meier analysis 50 squamous cell lung cancer 50 Behcet uveitis 50 Hypoactive Sexual Desire Disorder 50 AIR CF3 50 poor metabolizers 50 thyrotropin levels 50 Parkinson disease PD 50 fasting blood glucose 50 Hp2 2 50 epigenomics 50 heterozygous FH 50 brimonidine 50 secondary hyperparathyroidism 50 photodamaged skin 50 attention-deficit/hyperactivity disorder ADHD 50 herpes zoster vaccine 50 CombAT 50 systolic hypertension 50 inflammatory acne 50 dapagliflozin plus 50 ATACAND 50 CEUS 50 flurpiridaz F 50 procalcitonin 50 type2 diabetes 50 Beta Carotene 50 anti VEGF 50 ALTTO 50 ANCHOR trial 50 dietary intake 50 Tom Misteli 50 Sprycel dasatinib 50 skeletal fluorosis 50 amnestic MCI 50 active comparator 50 ARCALYST ® rilonacept 50 cardioembolic stroke 50 Thorough QT TQT 50 ACOSOG Z# 50 Critical Limb Ischemia 50 HCV RESPOND 2 50 basal bolus regimen 50 vidofludimus 50 placebo controlled 50 F FDG PET